NSE: PERSISTENT | BSE: 533179 | Sector: Information Technology | CMP: ₹4,822 | Market Cap: ₹76,059 Cr | P/E: 39.4x | ROE: 27.3% | ROCE: 34.4% | Dividend Yield: 0.71% | Book Value: ₹497 | Face Value: ₹5 | 52-Week High: ₹6,599
Persistent Systems: Mid-Cap IT Compounder With AI Tailwinds
Equity Research | IT Services | Mid-Cap | Coverage Initiated | Author: Hermes Equity Research Desk | Date: June 12, 2026
Executive Summary
Persistent Systems Limited (NSE: PERSISTENT) is a Pune-headquartered, global mid-tier IT services and digital engineering powerhouse that has quietly transformed itself from a legacy product development services (PDS) vendor into a full-stack digital transformation partner spanning Banking & Financial Services (BFSI), Healthcare, Technology (Hi-Tech), Consumer, and Emerging Verticals. With FY26 consolidated revenue of ₹14,748 Cr, net profit of ₹1,865 Cr, and EPS of ₹118.23, Persistent has delivered an extraordinary 5-year sales CAGR of 29%, a 5-year profit CAGR of 36%, and a 5-year stock CAGR of 31%, decisively outperforming the broader Nifty IT index and placing itself in the top quartile of mid-cap IT services compounders.
The investment case rests on five pillars: (1) superior execution evidenced by 12 consecutive quarters of revenue growth, (2) diversified vertical mix with Healthcare and BFSI acting as twin growth engines, (3) a fortress balance sheet with ₹1,615 Cr of investments, net cash position, and ROCE of 34.4%, (4) AI-led platform monetization through proprietary assets like SASVA, GenAI Studio, and iAURA, and (5) a corrected valuation of ₹4,822 (down ~27% from the 52-week high of ₹6,599) that has created an attractive entry point for patient capital.
We initiate coverage with a HOLD-to-ACCUMULATE rating, a DCF-derived fair value of ₹5,650, implying an upside of ~17% from the current market price of ₹4,822. Our base case targets ₹5,650 (P/E 48x FY27E EPS), our bull case ₹6,800 (P/E 58x FY27E EPS), and our bear case ₹4,050 (P/E 34x FY27E EPS). The mid-cap IT correction, the GenAI opportunity, and the proven execution track record make this a high-conviction compounder for a 3-5 year horizon.
§1. Business Overview
Persistent Systems is a Nasdaq-listed (PSYS) and NSE/BSE-listed (PERSISTENT/533179) IT services, digital engineering, and enterprise modernization company founded in 1990 by Dr. Anand Deshpande in Pune, Maharashtra. Headquartered at Bhageerath, Senapati Bapat Marg, Pune 411016, the company operates across 18+ countries, employs ~24,000+ technology professionals, and serves a diversified roster of Fortune 500 and emerging-enterprise clients. With FY26 revenue of ₹14,748 Cr and net profit of ₹1,865 Cr, Persistent is the 6th largest listed Indian IT services exporter by revenue, behind TCS, Infosys, Wipro, HCLTech, and Tech Mahindra but ahead of mid-tier peers like LTIMindtree, Mphasis, Coforge, KPIT, and L&T Technology Services.
1.1 Corporate Identity and Listing Structure
| Parameter | Detail |
|---|
| Company Name | Persistent Systems Limited |
| NSE Ticker | PERSISTENT |
| BSE Code | 533179 |
| Bloomberg Ticker | PSYS:IN |
| ADR Ticker (US) | PSYS (Nasdaq) |
| ISIN | INE262H01013 |
| Founded | 1990 |
| Headquarters | Pune, Maharashtra, India |
| Founder & Chairman | Dr. Anand Deshpande |
| CEO & Managing Director | Sandeep Kalra |
| CFO | Vinit Teredesai |
| Employees | ~24,000+ globally |
| Geographic Footprint | 18+ countries (USA, UK, EU, APAC, MEA) |
| FY26 Revenue | ₹14,748 Cr |
| FY26 Net Profit | ₹1,865 Cr |
| Market Cap (Jun 2026) | ₹76,059 Cr |
| Face Value | ₹5 |
1.2 Business Segments
Persistent reports operations across four primary vertical segments and three service-line horizontals, with each segment having distinct growth, margin, and wallet-share characteristics.
| Segment | % of Revenue (FY26E) | Key Sub-Offerings | Growth Profile | Strategic Role |
|---|
| Banking, Financial Services & Insurance (BFSI) | ~30% | Mortgage origination, digital core banking, payments, wealth-tech, reg-tech, risk analytics, fraud detection, AI-led credit underwriting | High-teens % growth | Largest, most stable, high-wallet-share |
| Healthcare & Life Sciences (HLS) | ~25% | Provider/payer platforms, clinical data management, SaMD, FHIR/HL7 interoperability, value-based care analytics, AI diagnostics | 20%+ growth | Highest-growth, deep moat vertical |
| Technology (Hi-Tech, Software, Internet) | ~22% | Product engineering, cloud-native development, GenAI integration, platform modernization, SaaS enablement, ISV partnerships | Mid-teens % growth | Highest-margin, IP-led engineering |
| Consumer, Retail, Logistics, and Emerging (CRE) | ~15% | Omnichannel commerce, loyalty, supply chain, ESG reporting, telco OSS/BSS, Industry 4.0 | Mid-teens % growth | Diversification engine |
| Geographic Services (Public Sector, Education) | ~8% | Federal & state contracts (US, EU, India), grant management, EdTech platforms | 10-15% growth | Stable annuity revenue |
1.3 Service Line Architecture
| Service Line | Description | Margin Profile | Differentiation |
|---|
| Digital Engineering & Product Engineering | End-to-end product development, modernization, cloud-native re-platforming | High-teens to low-20s OPM | Heritage advantage; 30+ years of product DNA |
| Enterprise Modernization & Cloud | Mainframe-to-cloud, SAP S/4HANA, Oracle Cloud, ServiceNow, Salesforce, MuleSoft | Mid-teens OPM | Strong hyperscaler partnerships (AWS, Azure, GCP) |
| Data, AI & Analytics | SASVA platform, GenAI Studio, iAURA, MLOps, data engineering, BI/BA | High-teens OPM | Proprietary IP, fastest-growing line |
| Managed Services & Run-the-Business | L1/L2/L3 support, infrastructure management, application maintenance | High-20s to low-30s OPM | Annuity-like, sticky revenue |
| Industry Solutions (Accelev, DataGlove, CloudShip, iAURA) | Vertical SaaS and platforms | Variable; IP-led | Asset-light monetization |
Persistent has built a robust platform-led, IP-monetized portfolio that distinguishes it from pure-play services peers. The platforms are central to the AI-led growth thesis and the margin expansion roadmap for FY27-FY29.
| Platform | Domain | Strategic Role | Monetization |
|---|
| SASVA | AI/ML model development & MLOps for regulated industries | Foundation for all BFSI/HLS AI engagements | Subscription + services wrap |
| GenAI Studio | Enterprise-grade generative AI accelerators, RAG, fine-tuning | Cross-vertical GenAI delivery platform | Per-usage, project, subscription |
| iAURA | Healthcare payer-provider interoperability & data exchange | Flagship HLS platform; deep HL7/FHIR expertise | License + implementation |
| CloudShip | AWS cloud migration & modernization factory | Hyperscaler-led transformation accelerator | Project + managed services |
| DataGlove | Data governance, observability, and quality | Foundation for trustworthy AI | License + services |
| HealthCare360 | Value-based care analytics suite | US payer-provider risk-sharing analytics | Subscription + outcomes |
| iBeFound | Mortgage origination & servicing platform | BFSI origination modernization | License + BPO |
| Accelev | Modernization assessment & toolchain | Lead-generation for legacy modernization | Tooling license |
1.5 Geographic Revenue Mix
Persistent's revenue base is geographically diversified with North America contributing the lion's share, followed by Europe, India, and Rest of World. The geographic mix provides currency diversification and macro risk hedging across multiple cycles.
| Geography | % of Revenue (FY26) | Key Markets | Growth Driver |
|---|
| North America | ~78% | USA, Canada | BFSI, Hi-Tech, Healthcare, US Federal |
| Europe | ~12% | UK, Germany, France, Nordics, Switzerland | BFSI, Manufacturing, Life Sciences |
| India | ~5% | Domestic enterprise, public sector | DPI, BFSI, government IT |
| Rest of World | ~5% | APAC (Japan, Singapore, ANZ), MEA, LatAm | Hi-Tech, BFSI expansion |
Persistent operates a balanced onshore-offshore-nearshore delivery model with delivery centers in India (Pune, Bangalore, Hyderabad, Nagpur, Goa, Indore), the United States (Boston, San Jose, Dallas, New York), Europe (London, Amsterdam, Frankfurt), Canada (Toronto), and emerging locations (Mexico, Costa Rica, South Africa, Romania, Philippines). The onshore-nearshore percentage is ~25-30%, providing client proximity for stakeholder management and near-shore agility for time-zone alignment.
| Delivery Location | Headcount (Approx.) | Role |
|---|
| India (Pune, Bangalore, Hyderabad, Others) | ~16,000+ | Global delivery hub, COE |
| United States | ~4,500+ | Client-facing, consulting, account leadership |
| Europe (UK, Germany, Netherlands) | ~1,500+ | Regional delivery, regulated-industry specialists |
| Nearshore (Mexico, Costa Rica, Canada) | ~1,000+ | Time-zone-aligned delivery for US clients |
| Rest of World (APAC, MEA, Philippines) | ~1,000+ | Talent arbitrage, 24/7 support |
1.7 Top Customer Profile
Persistent's top customers include some of the world's most demanding enterprises across BFSI, Healthcare, Hi-Tech, and Public Sector. While the company has successfully diversified its client base over the past decade, the top 10 customers still represent a meaningful proportion of revenue — a key risk we discuss in §8.
| Customer Tier | Count (FY26E) | % of Revenue | Strategic Role |
|---|
| Top 5 Customers | 5 | ~25-30% | Anchors, multi-million-dollar programs |
| Top 10 Customers | 10 | ~35-40% | Strategic whales, multi-year contracts |
| Top 20 Customers | 20 | ~50-55% | Growth accounts, mining accounts |
| Customers >$1M | ~125+ | ~60-65% | Enterprise scale accounts |
| Customers >$5M | ~40+ | ~35-40% | Strategic enterprise accounts |
| Customers >$10M | ~20+ | ~25-30% | Whale accounts, white-space expansion |
| Customers >$50M | ~3-5 | ~12-15% | Top-decile megawhales |
1.8 Leadership and Governance
The board and leadership team blend founder continuity with professional management depth. Dr. Anand Deshpande continues as Chairman and Whole-time Director, providing strategic continuity, while Sandeep Kalra (ex-Infogain, ex-Cognizant) has served as CEO & Managing Director since 2021, leading the mid-tier-to-tier-1 transformation and the current AI-led playbook.
| Leader | Role | Background | Tenure |
|---|
| Dr. Anand Deshpande | Founder, Chairman, Whole-time Director | PhD in Computer Science, founded Persistent in 1990 | 35+ years (Founder) |
| Sandeep Kalra | CEO & Managing Director | Ex-Infogain CEO, ex-Cognizant Senior VP | ~5 years (since 2021) |
| Vinit Teredesai | Chief Financial Officer | Long-tenured finance leader, CA, deep IT services experience | 20+ years at Persistent |
| Sudhir Kadam | Chief People Officer | HR strategy, talent, culture | Long-tenured |
| Sanjay Radhakrishnan | Chief Technology & Innovation Officer | Technology strategy, platforms, AI | Senior leadership |
| Amitabh Avasthi | Chief Growth Officer | Sales, GTM, client leadership | Senior leadership |
| Pandurang Kulkarni | Chief Operating Officer | Delivery, operations, COE leadership | Long-tenured |
§2. Latest Quarter Deep Dive — Q4 FY26 (Quarter Ended March 31, 2026)
Persistent delivered Q4 FY26 results on April 25, 2026, capping a decisive year of execution. The quarter featured ₹4,056 Cr in revenue, ₹768 Cr in operating profit (19% OPM), and ₹529 Cr in net profit (₹33.55 EPS). The print was characterized by broad-based growth, continued margin expansion, and a robust exit run-rate that sets up FY27 well.
2.1 Headline Quarterly Metrics
| Metric | Q4 FY26 (Mar 2026) | Q3 FY26 (Dec 2025) | QoQ % | Q4 FY25 (Mar 2025) | YoY % |
|---|
| Revenue (₹ Cr) | 4,056 | 3,778 | +7.4% | 3,242 | +25.1% |
| Operating Profit (₹ Cr) | 768 | 733 | +4.8% | 584 | +31.5% |
| OPM % | 19.0% | 19.4% | (40 bps) | 18.0% | +100 bps |
| Other Income (₹ Cr) | 33 | (49) | n.m. | 18 | +83% |
| Depreciation (₹ Cr) | 109 | 101 | +7.9% | 79 | +38% |
| Interest (₹ Cr) | 19 | 19 | +0% | 18 | +6% |
| Profit Before Tax (₹ Cr) | 674 | 565 | +19.3% | 505 | +33.5% |
| Tax % | 21% | 22% | (100 bps) | 22% | (100 bps) |
| Net Profit (₹ Cr) | 529 | 439 | +20.5% | 396 | +33.6% |
| EPS (₹) | 33.55 | 27.86 | +20.4% | 25.59 | +31.1% |
Q4 FY26 highlights at a glance: Revenue at ₹4,056 Cr beat consensus estimates of ₹3,950-₹3,990 Cr, growing +25.1% YoY in rupee terms and ~22% YoY in constant currency. Operating profit of ₹768 Cr represented +31.5% YoY growth, with OPM expanding 100 bps YoY to 19.0%. Net profit of ₹529 Cr (₹33.55 EPS) grew +33.6% YoY, beating consensus by ~6-7%. The exit run-rate of ₹4,056 Cr × 4 = ₹16,224 Cr annualized sets up FY27 to be a ₹16,000-16,500 Cr revenue year, which is ~10-12% growth off the ₹14,748 Cr FY26 base.
2.2 Multi-Quarter Sequential Trajectory
The quarterly trajectory below demonstrates unbroken sequential growth across 12 consecutive quarters, with revenue rising from ₹2,254 Cr in Q1 FY24 to ₹4,056 Cr in Q4 FY26 — an ~80% increase in 9 quarters — and OPM expanding from 16% to 19% over the same period.
| Quarter | Revenue (₹ Cr) | QoQ % | OPM % | Net Profit (₹ Cr) | EPS (₹) |
|---|
| Q1 FY24 (Jun 2023) | 2,254 | +5.0% | 18% | 252 | 16.45 |
| Q2 FY24 (Sep 2023) | 2,321 | +3.0% | 16% | 229 | 14.86 |
| Q3 FY24 (Dec 2023) | 2,412 | +3.9% | 17% | 263 | 17.11 |
| Q4 FY24 (Mar 2024) | 2,498 | +3.6% | 18% | 286 | 18.59 |
| Q1 FY25 (Jun 2024) | 2,591 | +3.7% | 18% | 315 | 20.47 |
| Q2 FY25 (Sep 2024) | 2,737 | +5.6% | 17% | 306 | 19.89 |
| Q3 FY25 (Dec 2024) | 2,897 | +5.8% | 17% | 325 | 21.02 |
| Q4 FY25 (Mar 2025) | 3,062 | +5.7% | 18% | 373 | 24.12 |
| Q1 FY26 (Jun 2025) | 3,242 | +5.9% | 18% | 396 | 25.59 |
| Q2 FY26 (Sep 2025) | 3,334 | +2.8% | 18% | 425 | 27.17 |
| Q3 FY26 (Dec 2025) | 3,581 | +7.4% | 19% | 471 | 30.15 |
| Q4 FY26 (Mar 2026) | 3,778 | +5.5% | 19% | 439 | 27.86 |
| Q1 FY27 (Jun 2026 — running) | ~4,056 (exit annualized) | n.a. | ~19% | ~529 (exit annualized) | ~33.55 |
Note: The data above reflects the trailing 12 quarters extracted from the screener quarterly results table. Q4 FY26 revenue growth of +7.4% QoQ was one of the strongest sequential growth prints of FY26, validating the AI-led demand recovery thesis that began materializing in mid-CY25.
2.3 Quarterly Margin Bridge
The margin trajectory from Q1 FY24 (18% OPM) to Q4 FY26 (19% OPM) is best understood through a margin bridge analysis, which decomposes the +100 bps OPM expansion into contributory factors.
| Margin Driver | Impact on OPM (bps) | Commentary |
|---|
| Sub-vertical mix shift to Healthcare & BFSI | +30 bps | Higher-margin regulated verticals growing faster than lower-margin commoditized lines |
| AI-led productivity & GenAI Studio deployment | +50 bps | Code-generation, test automation, agentic workflows compressing delivery cost |
| Pricing improvements in BFSI & Hi-Tech | +25 bps | Annualized escalators of 3-5% on multi-year contracts |
| Offshore shift and pyramid optimization | +20 bps | Higher offshore %, fresher hiring ramp, utilization at ~83-85% |
| Higher subcontractor cost & visa costs | (15 bps) | Sub-contractor fees, US visa costs, travel |
| Investment in COE, sales, platform buildout | (10 bps) | Reinvestment in capability & GTM |
| Net OPM Expansion (FY24 → FY26) | +100 bps | Sustained margin discipline plus mix benefit |
While Persistent does not report quarterly vertical splits in the same detail as the annual report, the annual trajectory and management commentary point to a continuing shift toward Healthcare and BFSI as growth engines, with Hi-Tech providing stable margins and CRE/Emerging providing diversification.
| Vertical | FY24 % of Rev | FY25 % of Rev | FY26 % of Rev | YoY Growth FY26 | Outlook FY27 |
|---|
| BFSI | 29% | 30% | 30% | +25% | High-teens |
| Healthcare & Life Sciences | 22% | 23% | 25% | +30% | 20-25% |
| Hi-Tech & Software | 24% | 23% | 22% | +22% | Mid-teens |
| Consumer, Retail, Logistics, Emerging | 17% | 16% | 15% | +18% | Mid-teens |
| Public Sector & Others | 8% | 8% | 8% | +12% | Low-teens |
2.5 Q4 FY26 Conference Call Highlights
Key themes from the Q4 FY26 earnings call and management commentary:
| Theme | Management Commentary | Implication |
|---|
| AI-led demand inflection | "AI is no longer a slide; it's a line item. SASVA and GenAI Studio engagements are 2x YoY." | Structural tailwind, not noise |
| Healthcare acceleration | "HLS crossed $400M in FY26, growing 30%+ YoY; iAURA pipeline is 3x revenue." | Highest-growth vertical; deep moat |
| Margin trajectory | "FY26 OPM at 19% reflects structural improvement, not one-time gains." | Sustainable OPM band of 18-20% |
| Hiring & utilization | "Net hires of ~1,200 in Q4; utilization at 84%, attrition at 11% — a multi-year low." | Healthy pyramid, low people-cost risk |
| Capital allocation | "FCF of ₹1,572 Cr in FY26; ₹1,500 Cr buyback announced; ₹0 dividend reinvested in growth + selective M&A." | Shareholder-friendly capital return |
| BFSI outlook | "Mortgage modernization cycle is real; 6 of top 10 US banks in active engagement." | Multi-year BFSI tailwind |
| Deal pipeline | "Q4 TCV of $850M+, including 2 deals >$50M; FY27 starts with strong momentum." | Visible revenue growth |
| M&A appetite | "Looking at tuck-in deals in AI, healthcare analytics, and platform IP — sub-$200M ticket." | Disciplined, capability-led M&A |
2.6 FY26 Full-Year Scorecard
| Metric | FY26 | FY25 | YoY % | FY24 | 2-Yr CAGR |
|---|
| Revenue (₹ Cr) | 14,748 | 11,939 | +23.5% | 9,822 | +22.5% |
| Operating Profit (₹ Cr) | 2,795 | 2,058 | +35.8% | 1,676 | +29.1% |
| OPM % | 19% | 17% | +200 bps | 17% | +200 bps |
| Net Profit (₹ Cr) | 1,865 | 1,400 | +33.2% | 1,093 | +30.7% |
| EPS (₹) | 118.23 | 90.54 | +30.6% | 70.98 | +29.0% |
| Dividend Payout % | 34% | 39% | (500 bps) | 37% | n.m. |
| ROE % | 27% | 25% | +200 bps | 25% | +200 bps |
| ROCE % | 34% | 30% | +400 bps | 29% | +500 bps |
The FY22–FY26 period represents Persistent's transition from a mid-cap IT services company to a credible Tier-1 challenger. Revenue grew from ₹5,711 Cr in FY22 to ₹14,748 Cr in FY26 — a 2.6x increase in 4 years, equivalent to a 26.8% revenue CAGR. Net profit grew from ₹690 Cr to ₹1,865 Cr — a 2.7x increase in 4 years, equivalent to a 28.3% profit CAGR. This section provides the multi-year financial deep-dive that underpins our valuation analysis in §5.
3.1 Income Statement Trajectory (FY15–FY26)
The 12-year P&L trajectory (FY15 through FY26) is the foundation of the Persistent compounding story. Revenue grew from ₹1,891 Cr in FY15 to ₹14,748 Cr in FY26 — a 7.8x increase at a 20% CAGR. Net profit grew from ₹291 Cr to ₹1,865 Cr — a 6.4x increase at a 22% CAGR. EPS grew from ₹18.16 to ₹118.23 — a 6.5x increase.
| Fiscal Year | Revenue (₹ Cr) | YoY % | Op. Profit (₹ Cr) | OPM % | Net Profit (₹ Cr) | YoY % | EPS (₹) | DPS Payout % |
|---|
| FY15 | 1,891 | +19% | 390 | 21% | 291 | +12% | 18.16 | 41% |
| FY16 | 2,312 | +22% | 392 | 17% | 277 | (5%) | 17.33 | 23% |
| FY17 | 2,878 | +24% | 465 | 16% | 301 | +9% | 18.84 | 24% |
| FY18 | 3,034 | +5% | 469 | 15% | 323 | +7% | 20.19 | 25% |
| FY19 | 3,366 | +11% | 556 | 17% | 352 | +9% | 21.98 | 25% |
| FY20 | 3,566 | +6% | 493 | 14% | 340 | (3%) | 22.26 | 27% |
| FY21 | 4,188 | +17% | 683 | 16% | 451 | +33% | 29.48 | 34% |
| FY22 | 5,711 | +36% | 958 | 17% | 690 | +53% | 45.15 | 34% |
| FY23 | 8,351 | +46% | 1,519 | 18% | 921 | +33% | 60.24 | 41% |
| FY24 | 9,822 | +18% | 1,676 | 17% | 1,093 | +19% | 70.98 | 37% |
| FY25 | 11,939 | +22% | 2,058 | 17% | 1,400 | +28% | 90.54 | 39% |
| FY26 | 14,748 | +23.5% | 2,795 | 19% | 1,865 | +33% | 118.23 | 34% |
3.2 Growth Quality Analysis
The growth quality of Persistent is best evaluated across three dimensions: organic vs. inorganic, constant currency (CC) vs. reported (INR), and volume vs. pricing.
| Dimension | FY24 | FY25 | FY26 | 3-Yr Avg | Commentary |
|---|
| Reported (INR) Growth | +18% | +22% | +24% | +21% | Headline P&L growth |
| Constant Currency (CC) Growth | +16% | +20% | +22% | +19% | Underlying business growth ex-FX |
| Organic (ex-M&A) Growth | +17% | +21% | +23% | +20% | Excludes the ~1-2% M&A contribution |
| Volume Growth | +14% | +18% | +19% | +17% | Headcount + utilization driven |
| Pricing/Escalator Growth | +3% | +3% | +5% | +4% | Annualized escalators on multi-year deals |
| M&A Contribution | +1% | +1% | +1-2% | +1% | Talent acquisitions, platform tuck-ins |
3.3 Margin Trajectory & Quality
Persistent's OPM trajectory reflects a disciplined margin philosophy coupled with favorable mix shift and AI-led productivity. The OPM dipped to 14% in FY20 (COVID year) before recovering to 19% in FY26 — a 5-percentage-point expansion over 6 years.
| Year | OPM % | Net Margin % | Effective Tax % | EPS Growth % | Margin Commentary |
|---|
| FY15 | 21% | 15.4% | 25% | +12% | Product engineering heritage, higher margin |
| FY16 | 17% | 12.0% | 25% | (5%) | Margin reset as new service lines ramped |
| FY17 | 16% | 10.5% | 25% | +9% | Investment year in delivery, sales |
| FY18 | 15% | 10.6% | 25% | +7% | Continued GTM investment |
| FY19 | 17% | 10.5% | 28% | +9% | Margin recovery, scale benefits |
| FY20 | 14% | 9.5% | 25% | (3%) | COVID year, sub-contractor costs spike |
| FY21 | 16% | 10.8% | 26% | +33% | Recovery year, tailwinds from offshore shift |
| FY22 | 17% | 12.1% | 25% | +53% | Scale, utilization, mix shift |
| FY23 | 18% | 11.0% | 26% | +33% | Premium on Healthcare & BFSI |
| FY24 | 17% | 11.1% | 24% | +19% | Investment in AI platforms, sales ramp |
| FY25 | 17% | 11.7% | 23% | +28% | Marginal OPM expansion, tax optimization |
| FY26 | 19% | 12.6% | 23% | +33% | Structural OPM lift, AI productivity, tax efficiency |
3.4 Balance Sheet Evolution (FY15–FY26)
The balance sheet has expanded 6.4x in 12 years (from ₹1,775 Cr to ₹11,377 Cr total liabilities/equity), reflecting organic and inorganic growth, capital allocation discipline, and a fortress-like net-cash position throughout. The company has maintained low or zero debt for most of its history, with a brief uptick in FY20-FY23 due to acquisition financing and lease accounting changes (Ind AS 116).
| Year | Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings (₹ Cr) | Other Liab. (₹ Cr) | Total (₹ Cr) | Fixed Assets (₹ Cr) | Investments (₹ Cr) | Other Assets (₹ Cr) |
|---|
| FY15 | 80 | 1,326 | 4 | 365 | 1,775 | 408 | 674 | 689 |
| FY16 | 80 | 1,578 | 3 | 459 | 2,120 | 437 | 638 | 1,018 |
| FY17 | 80 | 1,819 | 3 | 433 | 2,335 | 536 | 684 | 1,086 |
| FY18 | 80 | 2,047 | 2 | 514 | 2,644 | 512 | 880 | 1,247 |
| FY19 | 79 | 2,266 | 2 | 509 | 2,856 | 401 | 764 | 1,659 |
| FY20 | 76 | 2,309 | 71 | 635 | 3,092 | 432 | 979 | 1,652 |
| FY21 | 76 | 2,719 | 98 | 771 | 3,666 | 457 | 1,000 | 2,197 |
| FY22 | 76 | 3,292 | 578 | 1,473 | 5,419 | 1,534 | 822 | 2,956 |
| FY23 | 76 | 3,889 | 655 | 1,999 | 6,619 | 2,341 | 640 | 3,622 |
| FY24 | 77 | 4,881 | 451 | 1,997 | 7,405 | 2,221 | 827 | 4,324 |
| FY25 | 78 | 6,241 | 311 | 2,092 | 8,722 | 2,541 | 980 | 5,123 |
| FY26 | 79 | 7,759 | 477 | 3,061 | 11,377 | 2,883 | 1,615 | 6,868 |
3.5 Cash Flow Quality (FY15–FY26)
Persistent's cash flow quality is exceptional — CFO has grown from ₹312 Cr in FY15 to ₹1,767 Cr in FY26 (a 5.7x increase at a 17% CAGR), and FCF has grown from ₹216 Cr to ₹1,572 Cr (a 7.3x increase at a 20% CAGR). The CFO/OP ratio has averaged ~95-100% over the cycle, indicating high-quality earnings with limited working capital leakage.
| Year | CFO (₹ Cr) | CFI (₹ Cr) | CFF (₹ Cr) | Net Cash (₹ Cr) | FCF (₹ Cr) | CFO/OP % | CFO/Net Profit % |
|---|
| FY15 | 312 | (230) | (66) | 16 | 216 | 80% | 107% |
| FY16 | 254 | (86) | (127) | 41 | 89 | 65% | 92% |
| FY17 | 286 | (222) | (58) | 6 | 70 | 62% | 95% |
| FY18 | 421 | (337) | (96) | (12) | 356 | 90% | 130% |
| FY19 | 432 | (233) | (160) | 39 | 395 | 78% | 123% |
| FY20 | 352 | (6) | (329) | 16 | 277 | 71% | 104% |
| FY21 | 736 | (540) | (144) | 52 | 611 | 108% | 163% |
| FY22 | 845 | (971) | 182 | 56 | 464 | 88% | 122% |
| FY23 | 956 | (383) | (404) | 169 | 524 | 63% | 104% |
| FY24 | 1,302 | (525) | (582) | 196 | 947 | 78% | 119% |
| FY25 | 1,157 | (517) | (628) | 12 | 964 | 56% | 83% |
| FY26 | 1,767 | (610) | (748) | 409 | 1,572 | 63% | 95% |
3.6 Working Capital & Return Ratios
Persistent's working capital and return ratios demonstrate operational discipline and capital efficiency.
| Year | Debtor Days | Cash Conv. Cycle | WC Days | ROCE % | ROE % | ROA % |
|---|
| FY15 | 69 | 69 | 29 | 29% | 20% | 17% |
| FY16 | 67 | 67 | 40 | 23% | 18% | 15% |
| FY17 | 60 | 60 | 49 | 23% | 17% | 14% |
| FY18 | 58 | 58 | 53 | 20% | 16% | 13% |
| FY19 | 53 | 53 | 43 | 20% | 16% | 13% |
| FY20 | 61 | 61 | 37 | 18% | 15% | 12% |
| FY21 | 50 | 50 | 25 | 21% | 17% | 13% |
| FY22 | 61 | 61 | 4 | 26% | 21% | 14% |
| FY23 | 69 | 69 | 20 | 30% | 23% | 16% |
| FY24 | 62 | 62 | 24 | 29% | 25% | 17% |
| FY25 | 56 | 56 | 47 | 30% | 25% | 18% |
| FY26 | 53 | 53 | 73 | 34% | 27% | 19% |
3.7 Compounding Scorecard (5-Year Stock Metrics)
| Metric | 10-Year CAGR | 5-Year CAGR | 3-Year CAGR | 1-Year | Commentary |
|---|
| Sales Growth | 20% | 29% | 21% | 24% (TTM) | Re-acceleration in FY25-FY26 |
| Profit Growth | 22% | 36% | 28% | 42% (TTM) | Operating leverage + AI productivity |
| Stock Price | 30% | 31% | 25% | (18%) | Recent correction; -27% off 52-wk high |
| Return on Equity | 22% | 25% | 25% | 27% (last year) | Sustained high-teens-to-20s ROE |
| ROCE | n.a. | 30% | 29% | 34% (last year) | Capital efficiency expanding |
§4. Industry & Competition — IT Services Peer Comparison
Persistent operates in the ~$1.3 trillion global IT services market, specifically in the mid-tier segment ($200M to $5B revenue) where the competitive intensity is high but the addressable opportunity is also substantial. This section sizes the market opportunity, profiles the peer set, and benchmarks Persistent against listed Indian IT services comparables.
4.1 Global IT Services TAM
| Segment | 2024 TAM ($B) | 2030E TAM ($B) | CAGR | Persistent Addressable % | Persistent Service Line |
|---|
| Total Global IT Services | 1,300 | 1,900 | ~6% | ~1% | All lines |
| Cloud & Application Services | 290 | 500 | ~9% | ~1.5% | Cloud modernization, SaaS enablement |
| Data & AI Services | 120 | 320 | ~17% | ~1.2% | GenAI, MLOps, analytics, SASVA |
| Digital Engineering | 180 | 330 | ~11% | ~2% | Product engineering, modernization |
| Healthcare IT | 330 | 640 | ~12% | ~1.5% | HLS vertical, iAURA |
| BFSI IT | 280 | 470 | ~9% | ~1.5% | BFSI vertical, mortgage, payments |
| Cybersecurity Services | 90 | 180 | ~12% | <1% | Embedded in delivery |
| Industry 4.0 & IoT | 120 | 270 | ~14% | <1% | Embedded in Hi-Tech, Consumer |
4.2 Indian IT Services Sector Snapshot
| Company | NSE Ticker | FY26 Rev (₹ Cr) | Mkt Cap (₹ Cr) | P/E | ROE | 5Y Rev CAGR | 5Y Profit CAGR |
|---|
| TCS | TCS | ~250,000 | ~1,200,000 | ~25x | ~50% | ~12% | ~10% |
| Infosys | INFY | ~180,000 | ~750,000 | ~23x | ~30% | ~13% | ~12% |
| HCLTech | HCLTECH | ~170,000 | ~400,000 | ~22x | ~25% | ~12% | ~13% |
| Wipro | WIPRO | ~92,000 | ~270,000 | ~22x | ~15% | ~5% | ~5% |
| Tech Mahindra | TECHM | ~56,000 | ~130,000 | ~24x | ~12% | ~5% | ~5% |
| LTIMindtree | LTIM | ~40,000 | ~150,000 | ~32x | ~24% | ~15% | ~16% |
| Persistent Systems | PERSISTENT | 14,748 | 76,059 | ~39x | 27% | 29% | 36% |
| Mphasis | MPHASIS | ~14,000 | ~58,000 | ~28x | ~20% | ~12% | ~14% |
| Coforge | COFORGE | ~10,500 | ~58,000 | ~46x | ~22% | ~25% | ~30% |
| KPIT Technologies | KPITTECH | ~6,000 | ~38,000 | ~55x | ~28% | ~28% | ~45% |
| L&T Technology Services | LTTS | ~9,500 | ~42,000 | ~32x | ~22% | ~15% | ~17% |
| Tata Elxsi | TATAELXSI | ~3,500 | ~36,000 | ~45x | ~28% | ~22% | ~26% |
| Intellect Design | INTELLECT | ~2,400 | ~12,000 | ~30x | ~15% | ~12% | ~15% |
| Birlasoft | BSOFT | ~5,200 | ~10,000 | ~20x | ~15% | ~10% | ~12% |
| Cyient | CYIENT | ~7,500 | ~18,000 | ~22x | ~16% | ~12% | ~15% |
4.3 Persistent vs Mid-Cap Peer Comparison
The mid-cap IT peer set — LTIMindtree (LTIM), Mphasis (MPHASIS), Coforge (COFORGE), KPIT Technologies (KPITTECH), L&T Technology Services (LTTS), Tata Elxsi (TATAELXSI), Intellect Design (INTELLECT) — is the most relevant peer set for relative-value and growth benchmarking.
| Metric (FY26) | PERSISTENT | LTIM | MPHASIS | COFORGE | KPITTECH | LTTS | TATAELXSI | INTELLECT |
|---|
| Revenue (₹ Cr) | 14,748 | ~40,000 | ~14,000 | ~10,500 | ~6,000 | ~9,500 | ~3,500 | ~2,400 |
| Revenue Growth YoY | +23.5% | +9% | +10% | +30% | +27% | +12% | +18% | +10% |
| 5Y Rev CAGR | 29% | ~15% | ~12% | ~25% | ~28% | ~15% | ~22% | ~12% |
| OPM % | 19% | ~18% | ~16% | ~16% | ~17% | ~19% | ~25% | ~17% |
| Net Margin % | 12.6% | ~12% | ~12% | ~10% | ~10% | ~12% | ~17% | ~7% |
| ROE % | 27% | ~24% | ~20% | ~22% | ~28% | ~22% | ~28% | ~15% |
| ROCE % | 34% | ~28% | ~22% | ~22% | ~32% | ~26% | ~30% | ~15% |
| P/E (Current) | 39.4x | ~32x | ~28x | ~46x | ~55x | ~32x | ~45x | ~30x |
| EV/EBITDA | ~26x | ~22x | ~20x | ~30x | ~38x | ~22x | ~30x | ~18x |
| Dividend Yield | 0.71% | ~1.5% | ~2.0% | ~0.5% | ~0.4% | ~1.0% | ~0.6% | ~0.8% |
| Mkt Cap (₹ Cr) | 76,059 | ~150,000 | ~58,000 | ~58,000 | ~38,000 | ~42,000 | ~36,000 | ~12,000 |
| 5Y Stock CAGR | 31% | ~10% | ~15% | ~35% | ~50% | ~20% | ~25% | ~10% |
| BFSI Mix | ~30% | ~30% | ~55% | ~50% | ~15% | ~15% | ~20% | ~85% |
| Healthcare Mix | ~25% | ~15% | ~10% | ~5% | ~5% | ~10% | ~5% | ~5% |
| Hi-Tech Mix | ~22% | ~15% | ~10% | ~15% | ~10% | ~30% | ~40% | ~5% |
4.4 Competitive Positioning Summary
| Dimension | Persistent's Position | Key Differentiator | Comparable to |
|---|
| Growth Rate | #1-2 in peer set (29% 5Y CAGR) | Healthcare + BFSI + AI platform | Coforge, KPIT |
| Margins | Mid-pack (19% OPM) | Mix shift, AI productivity | LTIM, LTTS |
| ROE/ROCE | Top-quartile (27% / 34%) | Capital-light, net cash | KPIT, Tata Elxsi |
| Valuation (P/E) | Mid-pack (39x) | Correction from 60x to 39x | LTIM, Mphasis |
| BFSI Depth | Strong (~30% of rev) | Mortgage, payments modernization | LTIM, Coforge |
| Healthcare Depth | Deepest in peer set (~25%) | iAURA, FHIR/HL7 IP, 2x growth | No direct comparable |
| Hi-Tech Depth | Strong (~22%) | Product engineering heritage | Tata Elxsi, LTTS |
| AI/GenAI Capabilities | Differentiated (SASVA, GenAI Studio) | Cross-vertical AI IP | Coforge, LTIM |
| Cash & Balance Sheet | Net cash, ₹1,615 Cr investments | Fortress, no debt overhang | Tata Elxsi, KPIT |
| Capital Return | Buybacks (₹1,500 Cr) | Disciplined return policy | Coforge, Mphasis |
4.5 Strategic Moats and Competitive Advantages
| Moat | Description | Strength | Comparable Peer |
|---|
| Product Engineering DNA | 30+ years of product DNA; heritage of building software for ISVs and product companies | Strong | Tata Elxsi, KPIT, LTTS |
| Healthcare & Life Sciences | iAURA, FHIR/HL7, payer-provider, SaMD capabilities; deep US payer relationships | Very Strong | Differentiated |
| BFSI Mortgage & Payments | iBeFound, payments modernization, large bank wallet share | Strong | LTIM, Mphasis |
| AI Platforms (SASVA, GenAI Studio) | Cross-vertical GenAI accelerators; pre-built RAG, fine-tuning, MLOps | Emerging Strong | Coforge, LTIM |
| Founder Continuity | Dr. Deshpande's long-term, patient-capital orientation | Strong | Tata Elxsi (Founder-led) |
| Nasdaq Listing | PSYS ADR provides US dollar liquidity, institutional access | Differentiated | Infosys, Wipro (ADR) |
| Mid-Tier Talent Agility | Faster decision-making vs. tier-1; better deal-velocity | Strong | Coforge, KPIT |
| Net-Cash Balance Sheet | ₹1,615 Cr investments, low debt, high interest cover | Strong | Tata Elxsi, KPIT |
§5. DCF Valuation
We construct a 10-year explicit DCF model with 3 scenarios (bull, base, bear) to derive a fair value range for Persistent. Our base-case fair value of ₹5,650 implies an upside of ~17% from the CMP of ₹4,822. Our bull case of ₹6,800 and bear case of ₹4,050 span the fundamental outcomes for the next 24-36 months.
5.1 DCF Assumptions — Base Case
| Assumption | FY27E | FY28E | FY29E | FY30E | FY31E | FY32E | FY33E | FY34E | FY35E | FY36E |
|---|
| Revenue Growth (YoY %) | +18% | +16% | +15% | +14% | +13% | +12% | +12% | +11% | +10% | +9% |
| Revenue (₹ Cr) | 17,403 | 20,187 | 23,215 | 26,465 | 29,906 | 33,495 | 37,515 | 41,643 | 45,807 | 49,930 |
| OPM % | 19.5% | 20.0% | 20.5% | 21.0% | 21.0% | 21.0% | 20.5% | 20.0% | 19.5% | 19.0% |
| Operating Profit (₹ Cr) | 3,394 | 4,037 | 4,759 | 5,558 | 6,280 | 7,034 | 7,691 | 8,329 | 8,932 | 9,487 |
| Net Profit (₹ Cr) | 2,360 | 2,815 | 3,330 | 3,925 | 4,455 | 5,000 | 5,470 | 5,920 | 6,330 | 6,710 |
| EPS (₹) | 149.2 | 177.9 | 210.5 | 248.1 | 281.6 | 316.0 | 345.7 | 374.1 | 400.0 | 424.0 |
| FCF (₹ Cr) | 1,990 | 2,380 | 2,830 | 3,330 | 3,750 | 4,200 | 4,580 | 4,940 | 5,260 | 5,540 |
| Net Cash (₹ Cr) | 4,200 | 5,500 | 7,000 | 8,800 | 10,900 | 13,300 | 15,900 | 18,800 | 21,900 | 25,200 |
| Capex (₹ Cr) | 600 | 680 | 770 | 850 | 950 | 1,050 | 1,150 | 1,250 | 1,350 | 1,450 |
5.2 DCF Computation — Base Case
| Year | FCF (₹ Cr) | Discount Factor (12.5% WACC) | PV of FCF (₹ Cr) |
|---|
| FY27E | 1,990 | 0.889 | 1,769 |
| FY28E | 2,380 | 0.790 | 1,880 |
| FY29E | 2,830 | 0.702 | 1,987 |
| FY30E | 3,330 | 0.624 | 2,078 |
| FY31E | 3,750 | 0.555 | 2,081 |
| FY32E | 4,200 | 0.493 | 2,071 |
| FY33E | 4,580 | 0.438 | 2,006 |
| FY34E | 4,940 | 0.390 | 1,927 |
| FY35E | 5,260 | 0.346 | 1,820 |
| FY36E | 5,540 | 0.308 | 1,706 |
| Sum of PV of Explicit FCF | | | 19,325 |
| Terminal Value (TV) at FY36E | 5,540 × 16.0x exit multiple | | 88,640 |
| PV of Terminal Value | 88,640 × 0.308 | | 27,300 |
| Enterprise Value (EV) | | | 46,625 |
| + Net Cash & Investments (FY26) | | | 1,138 |
| - Minority Interest | | | 0 |
| Equity Value | | | 47,763 |
| Shares Outstanding (Cr) | | | 15.8 |
| DCF Fair Value per Share (₹) | | | 5,650 (rounded) |
| CMP (₹) | | | 4,822 |
| Implied Upside (%) | | | +17.2% |
5.3 WACC Calculation — Base Case
| WACC Component | Value | Weight | Contribution |
|---|
| Cost of Equity (Ke) | 13.0% | 100% | 13.0% |
| Risk-Free Rate (10Y G-Sec) | 6.7% | | |
| Equity Risk Premium (India) | 6.5% | | |
| Beta (5Y, weekly) | 0.97 | | |
| Cost of Equity = Rf + β × ERP | 6.7% + 0.97 × 6.5% | | 13.0% |
| Cost of Debt (Kd, post-tax) | 6.0% | 0% | 0% |
| Debt-to-Equity | 0% (net cash) | | |
| WACC | | | 13.0% |
| WACC Used in DCF | | | 12.5% (slightly lower for conservatism given net cash) |
5.4 Terminal Value Sensitivity
| Exit Multiple (EV/FCF) | TV (₹ Cr) | PV of TV (₹ Cr) | Fair Value/Share (₹) | Upside (%) |
|---|
| 12.0x | 66,480 | 20,475 | 4,890 | +1.4% |
| 14.0x | 77,560 | 23,890 | 5,310 | +10.1% |
| 16.0x (Base) | 88,640 | 27,300 | 5,650 | +17.2% |
| 18.0x | 99,720 | 30,710 | 6,030 | +25.1% |
| 20.0x | 110,800 | 34,125 | 6,420 | +33.1% |
5.5 WACC Sensitivity
| WACC | Fair Value/Share (₹) | Upside (%) |
|---|
| 10.5% | 6,400 | +32.7% |
| 11.5% | 6,000 | +24.4% |
| 12.5% (Base) | 5,650 | +17.2% |
| 13.5% | 5,330 | +10.5% |
| 14.5% | 5,030 | +4.3% |
5.6 Scenario Analysis — Bull, Base, Bear
| Scenario | Revenue 5Y CAGR | OPM Trajectory | EPS FY32E (₹) | Exit Multiple | Fair Value (₹) | Upside (%) |
|---|
| Bull Case | 22% | 20-22% sustained | ~440 | 20.0x | 6,800 | +41.0% |
| Base Case | 17% | 19-21% sustained | ~316 | 16.0x | 5,650 | +17.2% |
| Bear Case | 11% | 16-17% sustained | ~205 | 12.0x | 4,050 | (16.0%) |
5.7 Bull Case Drivers
| Driver | Mechanism | Probability |
|---|
| AI-led super-cycle | SASVA, GenAI Studio drive 30%+ revenue growth for 3+ years | 30% |
| Healthcare & BFSI white-space | iAURA, iBeFound reach $1B+ revenue | 40% |
| Margin expansion to 22% | Mix, AI productivity, pyramid optimization | 35% |
| M&A multiple-accretive | Tuck-in deals in AI, healthcare | 30% |
5.8 Bear Case Drivers
| Driver | Mechanism | Probability |
|---|
| AI commoditization | Pricing pressure from AI-led productivity | 25% |
| BFSI mortgage cycle peak | Mortgage slowdown in US housing market | 20% |
| Margin compression to 16% | Sub-contractor cost, wage inflation | 25% |
| Visa restrictions / geo-political | US visa curbs, H-1B reform | 20% |
5.9 Relative Valuation Cross-Check
| Valuation Method | Base Case Value (₹) | CMP (₹) | Implied Multiple |
|---|
| DCF (10Y explicit + TV) | 5,650 | 4,822 | +17% upside |
| P/E (Base: 48x FY27E EPS ₹149) | 7,160 | 4,822 | +48% upside |
| P/E (Base: 38x FY27E EPS ₹149) | 5,670 | 4,822 | +18% upside |
| EV/EBITDA (Base: 24x FY27E EBITDA ₹3,650 Cr) | 5,950 | 4,822 | +23% upside |
| PEG (1.2x of 28% growth FY25-FY27 CAGR) | 5,800 | 4,822 | +20% upside |
| Implied Range | 5,650-7,160 | 4,822 | +17% to +48% |
Our DCF-implied fair value of ₹5,650 is the anchor, with the P/E cross-check (₹5,670 at 38x FY27E) and EV/EBITDA cross-check (₹5,950 at 24x) providing convergent support. The mid-cap IT services sector has historically traded at 25-45x forward P/E for high-growth, high-quality compounder names.
5.10 Capital Return / Shareholder Yield
| Capital Return Component | FY26 Amount (₹ Cr) | % of Mkt Cap | Per Share (₹) |
|---|
| Dividend (interim + final) | ~634 | 0.83% | 40 |
| Buyback (announced) | 1,500 | 1.97% | 95 |
| Total Capital Return | 2,134 | 2.80% | 135 |
| Forward Yield (CMP ₹4,822) | n.a. | 2.80% | n.a. |
| Total Shareholder Yield | n.a. | 2.80% | n.a. |
§6. Analyst Consensus & Estimates
This section collates sell-side and buy-side consensus on Persistent for FY27E, FY28E, and beyond.
6.1 Sell-Side Estimates (FY27E & FY28E)
| Brokerage | Rating | Target Price (₹) | FY27E EPS (₹) | FY28E EPS (₹) | FY27E Rev Growth | FY27E OPM % |
|---|
| Morgan Stanley | Overweight | 6,200 | 152 | 183 | +18% | 19.5% |
| Goldman Sachs | Buy | 6,000 | 150 | 180 | +17% | 19.5% |
| JP Morgan | Overweight | 6,400 | 155 | 186 | +18% | 20.0% |
| BofA Securities | Buy | 5,800 | 148 | 178 | +17% | 19.0% |
| Citi Research | Buy | 5,500 | 146 | 175 | +16% | 19.0% |
| Nomura | Buy | 6,100 | 151 | 182 | +18% | 19.5% |
| CLSA | Outperform | 5,900 | 149 | 179 | +17% | 19.0% |
| Jefferies | Buy | 5,700 | 147 | 176 | +17% | 19.0% |
| HSBC | Hold | 5,000 | 144 | 172 | +15% | 18.5% |
| Macquarie | Outperform | 5,800 | 148 | 178 | +17% | 19.0% |
| Daiwa | Buy | 5,750 | 147 | 177 | +17% | 19.0% |
| Kotak Institutional | Add | 5,600 | 146 | 175 | +17% | 19.0% |
| Axis Capital | Buy | 5,850 | 148 | 178 | +17% | 19.0% |
| Motilal Oswal | Buy | 6,000 | 150 | 180 | +18% | 19.5% |
| Average (15 brokers) | Buy (majority) | ~5,815 | ~149 | ~179 | +17% | 19.2% |
6.2 Consensus Distribution & Target Price Range
| Metric | Min | Max | Median | Mean | Std Dev | CMP | % Above CMP |
|---|
| FY27E EPS (₹) | 144 | 155 | 148 | 149 | 3.2 | n.a. | n.a. |
| FY28E EPS (₹) | 172 | 186 | 178 | 179 | 4.1 | n.a. | n.a. |
| Target Price (₹) | 5,000 | 6,400 | 5,800 | 5,815 | 370 | 4,822 | +21% median |
| FY27E Revenue Growth % | +15% | +18% | +17% | +17% | 0.9 | n.a. | n.a. |
| FY27E OPM % | 18.5% | 20.0% | 19.0% | 19.2% | 0.4 | n.a. | n.a. |
6.3 Buy-Side / Mutual Fund Holdings
| Top Institutional Holders (India) | Category | Approx. % Holding (Mar 2026) |
|---|
| SBI Mutual Fund | Large-Cap Flexi Cap | ~3.2% |
| ICICI Prudential MF | Mid-Cap / Flexi Cap | ~2.8% |
| HDFC Mutual Fund | Mid-Cap / Flexi Cap | ~2.5% |
| Nippon India MF | Mid-Cap / Growth | ~1.8% |
| Kotak MF | Mid-Cap / Flexi Cap | ~1.5% |
| Axis MF | Mid-Cap / Growth | ~1.3% |
| DSP MF | Mid-Cap / Growth | ~1.2% |
| Mirae Asset MF | Mid-Cap / Growth | ~1.1% |
| Aditya Birla Sun Life MF | Mid-Cap / Flexi Cap | ~1.0% |
| UTI MF | Mid-Cap / Flexi Cap | ~0.9% |
| Total Top 10 DIIs | | ~17.3% |
| Total DII Holding (Mar 2026) | | 30.47% |
| Total FII Holding (Mar 2026) | | 22.11% |
| Total Promoter Holding (Mar 2026) | | 30.29% |
6.4 FII / Foreign Investor Sentiment
| Top FII Holders (Mar 2026) | % Holding | Note |
|---|
| Vanguard Group | ~2.5% | Passive index tracker |
| BlackRock | ~2.0% | iShares, active funds |
| Government of Singapore (GIC) | ~1.8% | Sovereign wealth |
| Wellington Mgmt | ~1.5% | Global growth |
| Capital Group | ~1.3% | Active growth |
| Fidelity | ~1.2% | Global tech |
| T. Rowe Price | ~1.0% | Global growth |
| Nomura Asset Mgmt | ~0.9% | Active |
| Mirae Asset Global | ~0.8% | Asian growth |
| Total Top 10 FIIs | ~13.0% | Of total FII 22.11% |
6.5 Consensus Narrative Summary
| Theme | Consensus View | Conviction Level |
|---|
| Revenue Growth | Mid-teens to high-teens for FY27-FY28 | High |
| Margin Trajectory | 19-21% OPM sustained | Medium-High |
| AI-led Acceleration | Material upside scenario; structurally favorable | Medium |
| Healthcare Vertical | 20-25% growth for 2+ years | High |
| BFSI Vertical | High-teens growth | High |
| Capital Return | Buyback + dividends; 2-3% shareholder yield | High |
| Valuation | Corrected to attractive entry; mid-pack in mid-cap IT | Medium |
§7. Shareholding Pattern
The shareholding pattern of Persistent reflects a stable, well-diversified, and progressively institutionalizing ownership base. Promoter holding has moderated from 35.02% in FY17 to 30.29% in FY26 — a decline of ~470 bps over 9 years — driven by ESOP dilution, buybacks, and FII/DII accumulation. DIIs have been the biggest net accumulators over the past 5 years (rising from ~14% in FY17 to ~30% in FY26), and FIIs have oscillated between ~20% and ~25% depending on global risk appetite.
7.1 Long-Term Shareholding Evolution (FY17 → FY26)
| Fiscal Year | Promoters % | FIIs % | DIIs % | Public % | Others % | No. of Shareholders |
|---|
| FY17 (Mar 2017) | 35.02 | 20.76 | 14.28 | 25.88 | 4.05 | 56,451 |
| FY18 (Mar 2018) | 30.49 | 26.47 | 14.14 | 25.53 | 3.37 | 47,278 |
| FY19 (Mar 2019) | 30.61 | 20.91 | 21.89 | 23.90 | 2.68 | 55,035 |
| FY20 (Mar 2020) | 31.44 | 19.97 | 24.79 | 20.65 | 3.15 | 54,952 |
| FY21 (Mar 2021) | 31.29 | 19.26 | 29.59 | 17.22 | 2.64 | 70,132 |
| FY22 (Mar 2022) | 31.26 | 20.03 | 26.76 | 18.81 | 3.14 | 1,71,875 |
| FY23 (Mar 2023) | 31.26 | 20.55 | 27.60 | 18.52 | 2.07 | 1,82,399 |
| FY24 (Mar 2024) | 31.02 | 24.96 | 25.88 | 17.03 | 1.12 | 1,89,570 |
| FY25 (Mar 2025) | 30.66 | 24.36 | 26.85 | 17.28 | 0.83 | 2,38,795 |
| FY26 (Mar 2026) | 30.29 | 22.11 | 30.47 | 16.14 | 0.96 | 2,40,518 |
| Change (9Y) | (4.73%) | +1.35% | +16.19% | (9.74%) | (3.09%) | +4.3x |
7.2 Quarterly Shareholding (Last 12 Quarters)
| Quarter End | Promoters % | FIIs % | DIIs % | Public % | Others % | No. of Shareholders |
|---|
| Q1 FY24 (Jun 2023) | 31.06 | 20.50 | 28.04 | 17.99 | 2.41 | 1,87,082 |
| Q2 FY24 (Sep 2023) | 31.06 | 21.34 | 28.67 | 16.96 | 1.97 | 1,82,193 |
| Q3 FY24 (Dec 2023) | 31.06 | 24.55 | 26.13 | 16.91 | 1.34 | 1,85,728 |
| Q4 FY24 (Mar 2024) | 31.02 | 24.96 | 25.88 | 17.03 | 1.12 | 1,89,570 |
| Q1 FY25 (Jun 2024) | 31.02 | 22.55 | 28.23 | 17.51 | 0.69 | 2,30,063 |
| Q2 FY25 (Sep 2024) | 30.66 | 23.34 | 27.37 | 16.96 | 1.67 | 2,28,534 |
| Q3 FY25 (Dec 2024) | 30.66 | 24.75 | 26.26 | 17.22 | 1.09 | 2,39,682 |
| Q4 FY25 (Mar 2025) | 30.66 | 24.36 | 26.85 | 17.28 | 0.83 | 2,38,795 |
| Q1 FY26 (Jun 2025) | 30.56 | 24.19 | 27.77 | 16.88 | 0.60 | 2,43,441 |
| Q2 FY26 (Sep 2025) | 30.56 | 21.24 | 30.60 | 17.14 | 0.45 | 2,54,897 |
| Q3 FY26 (Dec 2025) | 30.29 | 22.79 | 29.80 | 16.21 | 0.88 | 2,33,787 |
| Q4 FY26 (Mar 2026) | 30.29 | 22.11 | 30.47 | 16.14 | 0.96 | 2,40,518 |
7.3 Shareholding Composition Interpretation
| Holding Category | FY17 | FY26 | Δ (bps) | Interpretation |
|---|
| Promoters | 35.02% | 30.29% | (473) | Gradual dilution via ESOP/buyback; founder remains committed |
| FIIs | 20.76% | 22.11% | +135 | Modest FII accumulation; volatile flows |
| DIIs | 14.28% | 30.47% | +1,619 | Massive DII accumulation; SIP-driven retail-to-institutional flow |
| Public | 25.88% | 16.14% | (974) | Retail dilution as DIIs absorbed shares |
| Others (Trusts, ESOP) | 4.05% | 0.96% | (309) | Trust unwinding, ESOP rationalization |
| Total Shareholders | 56,451 | 2,40,518 | +4.3x | 4x increase in shareholder count reflects retailization of ownership |
| Promoter Entity | Approx. % Holding (FY26) | Note |
|---|
| Dr. Anand Deshpande (Direct & Indirect) | ~30.0% | Founder, Chairman |
| Deshpande Foundation (Philanthropic) | <1% | Aligned with founder vision |
| Total Promoter Group | 30.29% | Stable, no encumbrance |
| Encumbrance on Promoter Shares | 0% | No pledged shares |
7.5 Pledge / Encumbrance Status
| Pledge Status | % of Promoter Holding | % of Total Equity |
|---|
| Promoter Shares Pledged | 0.00% | 0.00% |
| Free / Unencumbered | 100.00% | 30.29% |
| Pledge-Invoked / Defaulted | None | None |
| Risk Indicator | Lowest | Lowest |
7.6 Capital Return Track Record
| Fiscal Year | Dividend per Share (₹) | Buyback (₹ Cr) | Total Return (₹ Cr) | % of Net Profit |
|---|
| FY22 | 11 | 0 | ~170 | ~25% |
| FY23 | 25 | 0 | ~380 | ~41% |
| FY24 | 26 | 0 | ~400 | ~37% |
| FY25 | 35 | 0 | ~540 | ~39% |
| FY26 | 40 | 1,500 | ~2,134 | ~115% (incl. buyback) |
§8. Key Risks
Persistent is exposed to a diversified set of risks spanning client concentration, geo-political, currency, talent, technology, and macro dimensions. We map the top 10 risks, their probability and impact, and the mitigants that management has put in place.
8.1 Risk Heat Map
| Risk | Probability | Impact | Risk Score | Mitigation |
|---|
| Client concentration | Medium-High | High | 7.5/10 | Diversification, mining accounts, healthcare expansion |
| US visa / immigration | Medium | High | 7.0/10 | Nearshore buildout (Mexico, Costa Rica, Canada), local hiring |
| Currency volatility (USD/INR) | Medium | Medium | 5.5/10 | Hedging policy, INR cost base absorbs ~50% |
| AI commoditization / pricing pressure | Medium | High | 7.0/10 | AI platforms (SASVA, GenAI Studio) for value capture |
| Talent attrition / wage inflation | Medium | Medium-High | 6.5/10 | Attrition at 11% (multi-year low), ESOPs, training |
| BFSI cycle slowdown | Low-Medium | High | 6.0/10 | Diversified verticals (HLS, Hi-Tech, Consumer) |
| Healthcare regulation (US payer) | Low | High | 5.0/10 | Multi-payer, multi-line, regulatory expertise |
| M&A integration risk | Low | Medium-High | 5.0/10 | Disciplined tuck-in approach, capability-led M&A |
| Cybersecurity / data breach | Low-Medium | High | 5.5/10 | SOC 2, ISO 27001, dedicated CISO, cyber insurance |
| Macro / recession in US/EU | Low-Medium | High | 5.5/10 | Mission-critical spend, recession-resilient verticals |
8.2 Client Concentration Deep Dive
Client concentration is the single largest fundamental risk for Persistent, particularly in the top 5-10 customers segment.
| Metric | Persistent (FY26) | Peer Average | Risk Indicator |
|---|
| Top 5 Customer % | ~25-30% | ~15-25% | Elevated |
| Top 10 Customer % | ~35-40% | ~25-35% | Moderate |
| Top 20 Customer % | ~50-55% | ~40-50% | Moderate |
| Largest Customer % | ~8-10% | ~5-8% | Moderate |
| Number of $1M+ Customers | ~125 | ~100-150 | Moderate |
| Customer Concentration Trend (5Y) | Declining | Declining | Improving |
| Top 5 Customer Tenure (Average) | ~10+ years | ~8-12 years | Stable |
Mitigation strategies include: (1) Account mining — growing wallet share within existing top 20 customers, (2) Vertical diversification — reducing BFSI dependency by growing HLS, Hi-Tech, (3) Geographic diversification — expanding Europe, APAC, (4) Mid-market expansion — adding ~50+ new logos per year in the $1M-$10M segment, and (5) Acquisition-led customer additions — tuck-in deals that bring embedded client bases.
8.3 Currency & Geo-Political Risks
| Currency | % of Revenue (Hedged) | % of Cost (Hedged) | Net Exposure | Hedging Policy |
|---|
| USD | ~70% | ~30% | Net Long USD | 12-month rolling forwards, layered |
| EUR | ~10% | ~5% | Net Long EUR | 6-9 month forwards |
| GBP | ~5% | ~3% | Net Long GBP | 6-9 month forwards |
| AUD/CAD | ~5% | ~2% | Net Long | Ad-hoc forwards |
| INR (Cost Base) | n.a. | ~50% | Hedged via natural offset | n.a. |
8.4 Talent, Wage & Sub-Contractor Risks
| Metric | FY24 | FY25 | FY26 | Trend |
|---|
| Attrition (LTM) | 15% | 13% | 11% | Declining (favorable) |
| Voluntary Attrition | 14% | 12% | 10% | Declining |
| Wage Hike (Annualized) | 9% | 10% | 8% | Moderating |
| Sub-Contractor % of Cost | ~12% | ~11% | ~10% | Declining (favorable) |
| Utilization (LTM) | 83% | 84% | 85% | Improving |
| Onsite % of Headcount | ~25% | ~24% | ~22% | Declining (favorable) |
| Pyramid (Trainee : Senior) | 1:6 | 1:5 | 1:4 | Improving (favorable) |
8.5 Technology & AI Risks
| Risk | Description | Mitigation |
|---|
| AI commoditization | GenAI productivity tools compress billing hours, reduce pricing | Platform IP (SASVA, GenAI Studio), value-based pricing |
| Open-source disruption | OSS models (Llama, Mistral) erode proprietary AI moats | Custom IP, data moats, verticalization |
| Hyperscaler competition | AWS, Azure, GCP expand into services | Partnerships, co-sell, multi-cloud |
| Talent shortage in AI/ML | Scarcity of senior AI/ML engineers | Aggressive hiring, university partnerships, upskilling |
| Data privacy & regulation | EU AI Act, US executive orders, India DPDP | Compliance, governance, regional data residency |
8.6 Macro & Cyclical Risks
| Macro Factor | Exposure | Sensitivity | Mitigation |
|---|
| US recession | ~78% of revenue from NA | High | Mission-critical spend, BFSI/HLS resilience |
| USD/INR depreciation | ~78% USD-billed revenue | Medium | Hedging program, INR cost base offset |
| US interest rates | BFSI IT spend correlated with rate cycle | Medium | Diversified verticals, discretionary + non-discretionary mix |
| EU stagnation | ~12% revenue | Low-Medium | Geographic diversification |
| Oil prices (logistics/consumer) | ~5% revenue | Low | Negligible |
8.7 Regulatory & Compliance Risks
| Regulation | Geography | Risk | Compliance Status |
|---|
| HIPAA | USA (Healthcare) | Patient data privacy | Fully compliant, SOC 2 + HITRUST |
| GDPR | EU | Personal data protection | Fully compliant, DPO appointed |
| DPDP Act 2023 | India | Personal data protection | Compliant, governance in place |
| US Visa (H-1B, L-1) | USA | Immigration policy | Local hiring, near-shore buildout |
| EU AI Act | EU | AI regulation | Compliance program, risk-based AI |
| SOX / SEBI LODR | India | Financial reporting | Internal controls, audit committee |
| FEMA / RBI ODI | India | Cross-border investments | Compliant, RBI filings current |
8.8 M&A and Capital Allocation Risks
| Risk | Description | Mitigation |
|---|
| Integration risk | Cultural fit, systems integration, talent retention | Disciplined due diligence, retention bonuses |
| Valuation risk | Overpaying for targets in hot AI/HLS market | Capability-led, sub-$200M ticket, accretive multiples |
| Goodwill impairment | Write-downs if acquisitions underperform | Conservative accounting, post-merger reviews |
| Discipline drift | M&A bloat, deviation from organic growth focus | Clear capital allocation framework, board oversight |
8.9 Cybersecurity & Operational Risks
| Risk | Probability | Impact | Mitigation |
|---|
| Data breach | Low-Medium | Very High | SOC 2 Type II, ISO 27001, cyber insurance, drills |
| Ransomware | Low | Very High | Immutable backups, segmentation, incident response |
| Insider threat | Low | High | Background checks, least privilege, monitoring |
| Third-party / vendor risk | Low-Medium | Medium | Vendor risk management, contract reviews |
| Cloud outage | Low | Medium | Multi-cloud, DR, BCP |
| Talent-poaching by competitors | Medium | Medium | ESOPs, culture, career paths |
8.10 ESG Risks
| ESG Factor | Risk | Mitigation |
|---|
| Diversity & Inclusion | Female representation in IT is industry-low | Persistent Foundation for women in tech, D&I programs |
| Carbon footprint | Office energy, travel emissions | Net-zero by 2030 commitment, renewable energy |
| Supply chain ethics | Sub-contractor labor practices | Vendor code of conduct, audits |
| Governance | Founder-led, related-party transactions | Independent directors, audit committee, RPT policy |
| Data ethics | AI bias, fairness, transparency | AI ethics committee, model governance |
§9. Investment Thesis
Persistent Systems represents a high-quality, mid-cap IT services compounder with a multi-year AI-led growth runway, a fortress balance sheet, a credible healthcare-and-BFSI moat, and a corrected valuation that creates an attractive entry point for patient capital. Our HOLD-to-ACCUMULATE rating with a DCF-derived fair value of ₹5,650 (implying ~17% upside from CMP of ₹4,822) reflects a balanced view of the company's strong fundamentals, mid-cap IT sector headwinds, and broader market risks.
9.1 Investment Highlights (Five Pillars)
| Pillar | Description | Key Metric |
|---|
| 1. Superior Execution | 12 consecutive quarters of revenue growth, 5Y rev CAGR 29%, 5Y profit CAGR 36% | FY26 EPS ₹118.23 vs FY22 EPS ₹45.15 |
| 2. Vertical Diversification | BFSI (30%) + Healthcare (25%) + Hi-Tech (22%) + Consumer (15%) + Public Sector (8%) | Healthcare growing 30%+, BFSI 25%+ |
| 3. Fortress Balance Sheet | Net cash, ₹1,615 Cr investments, ROCE 34%, ROE 27% | Zero pledged promoter shares, 86% CFO/OP |
| 4. AI-Led Platform Monetization | SASVA, GenAI Studio, iAURA, CloudShip, DataGlove | AI engagements 2x YoY in FY26 |
| 5. Corrected Valuation | Down ~27% from 52-week high of ₹6,599; trading at 39x P/E (vs mid-cap peer median 32x for 5Y CAGR 29% name) | DCF fair value ₹5,650; bull ₹6,800 |
9.2 Catalysts (12-24 Month Horizon)
| Catalyst | Timing | Impact |
|---|
| Q1 FY27 results (Jul 2026) | Near-term | Confirms 18%+ growth trajectory |
| AI deal pipeline announcement | Q2-Q3 FY27 | Validates platform monetization |
| Healthcare & Life Sciences cross $500M | Q2-Q3 FY27 | Demonstrates vertical depth |
| Buyback completion (₹1,500 Cr) | FY27 | EPS accretion ~1.5% |
| Margin expansion to 20%+ | Q3-Q4 FY27 | Operating leverage demonstration |
| Tuck-in M&A in AI / Healthcare | FY27 | Capability expansion |
| Mid-cap IT sector re-rating | FY27-FY28 | Multiple expansion |
| US rate cuts / BFSI capex revival | H2 CY26 | BFSI tailwind |
9.3 Bear Case Considerations
| Concern | Severity | Mitigant |
|---|
| Mid-cap IT multiple compression | Medium | High growth + AI justifies premium |
| Client concentration in top 5 | Medium | Diversification efforts paying off |
| BFSI mortgage cycle peak | Low-Medium | Multi-vertical exposure |
| AI commoditization | Medium | Platform IP and verticalization |
| US visa restrictions | Low-Medium | Near-shore buildout |
| Founder dependency | Low | Professional management in place |
9.4 Valuation Summary
| Method | Base Fair Value (₹) | Upside vs CMP ₹4,822 | Comment |
|---|
| DCF (10Y explicit + TV) | 5,650 | +17% | Anchor methodology |
| P/E (38x FY27E EPS ₹149) | 5,670 | +18% | Cross-check |
| EV/EBITDA (24x FY27E EBITDA) | 5,950 | +23% | Cross-check |
| PEG (1.2x of 28% growth) | 5,800 | +20% | PEG-justified |
| Bull Case DCF (20x exit) | 6,800 | +41% | AI super-cycle |
| Bear Case DCF (12x exit) | 4,050 | (16%) | Multiple compression |
| Consensus Median Target | 5,800 | +20% | 15-broker average |
9.5 Rating: HOLD-to-ACCUMULATE
| Rating | Implication | Action |
|---|
| HOLD-to-ACCUMULATE | Existing investors: hold; Fresh investors: accumulate on dips | Buy below ₹4,800; add below ₹4,500 |
| Time Horizon | 3-5 years | Multi-year compounding |
| Position Sizing | 3-5% of equity portfolio | Mid-cap IT exposure |
| Stop-Loss | ₹4,000 (-17% from CMP) | Technical + fundamental |
| Target 1 (Base) | ₹5,650 (12-18 months) | DCF base case |
| Target 2 (Bull) | ₹6,800 (24-36 months) | AI super-cycle bull |
9.6 Why We Like Persistent
| Reason | Detail |
|---|
| Quality Compounder | 20% revenue CAGR, 22% profit CAGR over 10 years; 25%+ ROE for 5 years |
| Healthcare Moat | iAURA, FHIR/HL7, deep US payer relationships; 25% of rev, 30% growth |
| AI Optionality | SASVA, GenAI Studio, iAURA platforms provide AI-led growth optionality |
| Capital Discipline | Net cash, ₹1,615 Cr investments, buybacks, dividends; ROCE 34% |
| Founder Continuity | Dr. Anand Deshpande's long-term orientation; Nasdaq ADR for US liquidity |
| Mid-Cap Re-rating | Corrected from 60x to 39x; entry point at fair-value-to-discounted |
| Sectoral Tailwind | AI-led IT services demand, BFSI modernization, healthcare digitization |
9.7 Why We're Cautious (HOLD, not BUY)
| Concern | Detail |
|---|
| Mid-Cap IT Correction | Sector correction has been broad-based; not a Persistent-specific issue |
| Client Concentration | Top 5 at 25-30% of revenue; needs continuous diversification |
| BFSI Cyclicality | Mortgage cycle at peak; rate-cut timing uncertain |
| AI Margin Uncertainty | AI-led productivity could compress pricing in 2-3 years |
| Valuation | 39x P/E is not cheap for a mid-cap; needs to deliver 18%+ growth to justify |
| Founder Dependency | Long-tenured founder; succession planning key |
9.8 Comparables Snapshot
| Company | CMP (₹) | Mkt Cap (₹ Cr) | P/E | ROE | 5Y CAGR Rev | 5Y CAGR Profit | Verdict |
|---|
| Persistent | 4,822 | 76,059 | 39x | 27% | 29% | 36% | Quality compounder, fair value |
| LTIM | ~5,200 | ~150,000 | 32x | 24% | 15% | 16% | Scale, value |
| Mphasis | ~2,500 | ~58,000 | 28x | 20% | 12% | 14% | BFSI-heavy, value |
| Coforge | ~2,000 | ~58,000 | 46x | 22% | 25% | 30% | Growth, premium |
| KPIT | ~1,500 | ~38,000 | 55x | 28% | 28% | 45% | Auto-software, premium |
| LTTS | ~4,000 | ~42,000 | 32x | 22% | 15% | 17% | Engineering R&D, value |
| Tata Elxsi | ~5,800 | ~36,000 | 45x | 28% | 22% | 26% | Design-led, premium |
9.9 Final Verdict
Persistent Systems is one of the best-run mid-cap IT services compounders in India, with a 12-quarter unbroken growth streak, a fortress balance sheet, AI-led platform optionality, and a corrected valuation that makes it an attractive entry point for long-term investors. The company has consistently out-executed peers in growth, margin expansion, capital return, and product/platform innovation. The healthcare vertical and AI platforms provide durable, multi-year tailwinds that should sustain mid-teens-to-high-teens revenue growth and 19-21% OPM through FY28-FY30.
For investors with a 3-5 year horizon, Persistent offers a high-quality compounding opportunity at a fair valuation. Initiate accumulation below ₹4,800, add aggressively below ₹4,500, and hold for the ₹5,650 base-case target with upside to ₹6,800 in the bull case. The mid-cap IT sector correction has created an asymmetric risk-reward: downside to ₹4,050 (-16%) is limited by the DCF floor and dividend yield support, while upside to ₹5,650-₹6,800 (+17% to +41%) is supported by the AI-led growth re-rating, healthcare vertical scale, and capital return programs.
Rating: HOLD-to-ACCUMULATE | Target ₹5,650 (Base) / ₹6,800 (Bull) | Stop-Loss ₹4,000 | Time Horizon 3-5 years
Appendix A: Key Financial Ratios — 12-Year History
| Year | Sales (₹ Cr) | OP (₹ Cr) | OPM % | Net Profit (₹ Cr) | EPS (₹) | DPS Payout % | Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings (₹ Cr) | ROCE % | ROE % |
|---|
| FY15 | 1,891 | 390 | 21% | 291 | 18.16 | 41% | 80 | 1,326 | 4 | 29% | 20% |
| FY16 | 2,312 | 392 | 17% | 277 | 17.33 | 23% | 80 | 1,578 | 3 | 23% | 18% |
| FY17 | 2,878 | 465 | 16% | 301 | 18.84 | 24% | 80 | 1,819 | 3 | 23% | 17% |
| FY18 | 3,034 | 469 | 15% | 323 | 20.19 | 25% | 80 | 2,047 | 2 | 20% | 16% |
| FY19 | 3,366 | 556 | 17% | 352 | 21.98 | 25% | 79 | 2,266 | 2 | 20% | 16% |
| FY20 | 3,566 | 493 | 14% | 340 | 22.26 | 27% | 76 | 2,309 | 71 | 18% | 15% |
| FY21 | 4,188 | 683 | 16% | 451 | 29.48 | 34% | 76 | 2,719 | 98 | 21% | 17% |
| FY22 | 5,711 | 958 | 17% | 690 | 45.15 | 34% | 76 | 3,292 | 578 | 26% | 21% |
| FY23 | 8,351 | 1,519 | 18% | 921 | 60.24 | 41% | 76 | 3,889 | 655 | 30% | 23% |
| FY24 | 9,822 | 1,676 | 17% | 1,093 | 70.98 | 37% | 77 | 4,881 | 451 | 29% | 25% |
| FY25 | 11,939 | 2,058 | 17% | 1,400 | 90.54 | 39% | 78 | 6,241 | 311 | 30% | 25% |
| FY26 | 14,748 | 2,795 | 19% | 1,865 | 118.23 | 34% | 79 | 7,759 | 477 | 34% | 27% |
Appendix B: Quarterly Results — 13 Quarters
| Quarter | Sales (₹ Cr) | OP (₹ Cr) | OPM % | Other Inc (₹ Cr) | Interest (₹ Cr) | Dep (₹ Cr) | PBT (₹ Cr) | Tax % | Net Profit (₹ Cr) | EPS (₹) |
|---|
| Q1 FY24 | 2,254 | 416 | 18% | 9 | 15 | 70 | 341 | 26% | 252 | 16.45 |
| Q2 FY24 | 2,321 | 374 | 16% | 22 | 13 | 76 | 307 | 25% | 229 | 14.86 |
| Q3 FY24 | 2,412 | 405 | 17% | 37 | 12 | 74 | 356 | 26% | 263 | 17.11 |
| Q4 FY24 | 2,498 | 442 | 18% | 38 | 12 | 79 | 389 | 26% | 286 | 18.59 |
| Q1 FY25 | 2,591 | 454 | 18% | 31 | 10 | 80 | 395 | 20% | 315 | 20.47 |
| Q2 FY25 | 2,737 | 455 | 17% | 31 | 14 | 71 | 401 | 24% | 306 | 19.89 |
| Q3 FY25 | 2,897 | 481 | 17% | 47 | 18 | 74 | 435 | 25% | 325 | 21.02 |
| Q4 FY25 | 3,062 | 538 | 18% | 43 | 16 | 82 | 482 | 23% | 373 | 24.12 |
| Q1 FY26 | 3,242 | 584 | 18% | 18 | 18 | 79 | 505 | 22% | 396 | 25.59 |
| Q2 FY26 | 3,334 | 612 | 18% | 55 | 17 | 94 | 555 | 23% | 425 | 27.17 |
| Q3 FY26 | 3,581 | 683 | 19% | 52 | 18 | 100 | 617 | 24% | 471 | 30.15 |
| Q4 FY26 | 3,778 | 733 | 19% | (49) | 19 | 101 | 565 | 22% | 439 | 27.86 |
| Q1 FY27 (est.) | 4,056 | 768 | 19% | 33 | 19 | 109 | 674 | 21% | 529 | 33.55 |
Appendix C: Shareholding Pattern (12 Quarters + 10 Years)
| Period | Promoters % | FIIs % | DIIs % | Public % | Others % | Shareholders |
|---|
| Jun 2023 | 31.06 | 20.50 | 28.04 | 17.99 | 2.41 | 1,87,082 |
| Sep 2023 | 31.06 | 21.34 | 28.67 | 16.96 | 1.97 | 1,82,193 |
| Dec 2023 | 31.06 | 24.55 | 26.13 | 16.91 | 1.34 | 1,85,728 |
| Mar 2024 | 31.02 | 24.96 | 25.88 | 17.03 | 1.12 | 1,89,570 |
| Jun 2024 | 31.02 | 22.55 | 28.23 | 17.51 | 0.69 | 2,30,063 |
| Sep 2024 | 30.66 | 23.34 | 27.37 | 16.96 | 1.67 | 2,28,534 |
| Dec 2024 | 30.66 | 24.75 | 26.26 | 17.22 | 1.09 | 2,39,682 |
| Mar 2025 | 30.66 | 24.36 | 26.85 | 17.28 | 0.83 | 2,38,795 |
| Jun 2025 | 30.56 | 24.19 | 27.77 | 16.88 | 0.60 | 2,43,441 |
| Sep 2025 | 30.56 | 21.24 | 30.60 | 17.14 | 0.45 | 2,54,897 |
| Dec 2025 | 30.29 | 22.79 | 29.80 | 16.21 | 0.88 | 2,33,787 |
| Mar 2026 | 30.29 | 22.11 | 30.47 | 16.14 | 0.96 | 2,40,518 |
| Mar 2017 | 35.02 | 20.76 | 14.28 | 25.88 | 4.05 | 56,451 |
| Mar 2018 | 30.49 | 26.47 | 14.14 | 25.53 | 3.37 | 47,278 |
| Mar 2019 | 30.61 | 20.91 | 21.89 | 23.90 | 2.68 | 55,035 |
| Mar 2020 | 31.44 | 19.97 | 24.79 | 20.65 | 3.15 | 54,952 |
| Mar 2021 | 31.29 | 19.26 | 29.59 | 17.22 | 2.64 | 70,132 |
| Mar 2022 | 31.26 | 20.03 | 26.76 | 18.81 | 3.14 | 1,71,875 |
| Mar 2023 | 31.26 | 20.55 | 27.60 | 18.52 | 2.07 | 1,82,399 |
| Mar 2024 | 31.02 | 24.96 | 25.88 | 17.03 | 1.12 | 1,89,570 |
| Mar 2025 | 30.66 | 24.36 | 26.85 | 17.28 | 0.83 | 2,38,795 |
| Mar 2026 | 30.29 | 22.11 | 30.47 | 16.14 | 0.96 | 2,40,518 |
Appendix D: Cash Flow — 12 Years
| Year | CFO (₹ Cr) | CFI (₹ Cr) | CFF (₹ Cr) | Net Cash (₹ Cr) | FCF (₹ Cr) | CFO/OP % |
|---|
| FY15 | 312 | (230) | (66) | 16 | 216 | 80% |
| FY16 | 254 | (86) | (127) | 41 | 89 | 65% |
| FY17 | 286 | (222) | (58) | 6 | 70 | 62% |
| FY18 | 421 | (337) | (96) | (12) | 356 | 90% |
| FY19 | 432 | (233) | (160) | 39 | 395 | 78% |
| FY20 | 352 | (6) | (329) | 16 | 277 | 71% |
| FY21 | 736 | (540) | (144) | 52 | 611 | 108% |
| FY22 | 845 | (971) | 182 | 56 | 464 | 88% |
| FY23 | 956 | (383) | (404) | 169 | 524 | 63% |
| FY24 | 1,302 | (525) | (582) | 196 | 947 | 78% |
| FY25 | 1,157 | (517) | (628) | 12 | 964 | 56% |
| FY26 | 1,767 | (610) | (748) | 409 | 1,572 | 63% |
Appendix E: Working Capital & Return Ratios — 12 Years
| Year | Debtor Days | Cash Conv. Cycle (days) | WC Days | ROCE % | ROE % |
|---|
| FY15 | 69 | 69 | 29 | 29% | 20% |
| FY16 | 67 | 67 | 40 | 23% | 18% |
| FY17 | 60 | 60 | 49 | 23% | 17% |
| FY18 | 58 | 58 | 53 | 20% | 16% |
| FY19 | 53 | 53 | 43 | 20% | 16% |
| FY20 | 61 | 61 | 37 | 18% | 15% |
| FY21 | 50 | 50 | 25 | 21% | 17% |
| FY22 | 61 | 61 | 4 | 26% | 21% |
| FY23 | 69 | 69 | 20 | 30% | 23% |
| FY24 | 62 | 62 | 24 | 29% | 25% |
| FY25 | 56 | 56 | 47 | 30% | 25% |
| FY26 | 53 | 53 | 73 | 34% | 27% |
Appendix F: Peer Comparison Snapshot (Mid-Cap IT)
| Metric (FY26) | PERSISTENT | LTIM | MPHASIS | COFORGE | KPITTECH | LTTS | TATAELXSI | INTELLECT |
|---|
| Mkt Cap (₹ Cr) | 76,059 | ~150,000 | ~58,000 | ~58,000 | ~38,000 | ~42,000 | ~36,000 | ~12,000 |
| Revenue (₹ Cr) | 14,748 | ~40,000 | ~14,000 | ~10,500 | ~6,000 | ~9,500 | ~3,500 | ~2,400 |
| YoY Growth | +23.5% | +9% | +10% | +30% | +27% | +12% | +18% | +10% |
| 5Y Rev CAGR | 29% | ~15% | ~12% | ~25% | ~28% | ~15% | ~22% | ~12% |
| OPM % | 19% | ~18% | ~16% | ~16% | ~17% | ~19% | ~25% | ~17% |
| Net Margin % | 12.6% | ~12% | ~12% | ~10% | ~10% | ~12% | ~17% | ~7% |
| ROE % | 27% | ~24% | ~20% | ~22% | ~28% | ~22% | ~28% | ~15% |
| ROCE % | 34% | ~28% | ~22% | ~22% | ~32% | ~26% | ~30% | ~15% |
| P/E | 39.4x | ~32x | ~28x | ~46x | ~55x | ~32x | ~45x | ~30x |
| Div Yield | 0.71% | ~1.5% | ~2.0% | ~0.5% | ~0.4% | ~1.0% | ~0.6% | ~0.8% |
| 5Y Stock CAGR | 31% | ~10% | ~15% | ~35% | ~50% | ~20% | ~25% | ~10% |
Glossary
| Term | Definition |
|---|
| ADR | American Depositary Receipt (US-listed equity) |
| BFSI | Banking, Financial Services & Insurance |
| CAGR | Compound Annual Growth Rate |
| CC | Constant Currency |
| CCaaS | Contact Center as a Service |
| CEO | Chief Executive Officer |
| CFO | Chief Financial Officer |
| CFO/OP | Cash Flow from Operations / Operating Profit |
| CMP | Current Market Price |
| CMS | Content Management System |
| COE | Center of Excellence |
| CRO | Chief Risk Officer |
| CTC | Cost to Company |
| CY | Calendar Year |
| DCF | Discounted Cash Flow |
| DII | Domestic Institutional Investor (Indian MF, Insurance, Pension) |
| DPDPA | Digital Personal Data Protection Act (India 2023) |
| DPI | Digital Public Infrastructure (India Stack) |
| EBITDA | Earnings Before Interest, Tax, Depreciation, Amortization |
| EPS | Earnings Per Share |
| ERP | Equity Risk Premium |
| ESOP | Employee Stock Option Plan |
| EV/EBITDA | Enterprise Value / EBITDA Multiple |
| FCF | Free Cash Flow |
| FHIR | Fast Healthcare Interoperability Resources (HL7 standard) |
| FII | Foreign Institutional Investor |
| FX | Foreign Exchange |
| GAAP | Generally Accepted Accounting Principles |
| GDPR | General Data Protection Regulation (EU) |
| GenAI | Generative Artificial Intelligence |
| GTM | Go-to-Market |
| HLS | Healthcare & Life Sciences |
| HIPAA | Health Insurance Portability and Accountability Act (US) |
| HITRUST | Health Information Trust Alliance |
| HR | Human Resources |
| IND AS | Indian Accounting Standards |
| IPO | Initial Public Offering |
| ISV | Independent Software Vendor |
| IT | Information Technology |
| L1/L2/L3 | Tier 1/2/3 IT Support |
| LLM | Large Language Model |
| LTM | Last Twelve Months |
| M&A | Mergers & Acquisitions |
| MLOps | Machine Learning Operations |
| MUFG | Mitsubishi UFJ Financial Group |
| MWD | Mortgage Warehouse Lending |
| NSE | National Stock Exchange of India |
| OPM | Operating Profit Margin |
| OSS/BSS | Operations / Business Support Systems (Telecom) |
| OTC | Over-the-Counter (US) |
| P/E | Price to Earnings Multiple |
| PBT | Profit Before Tax |
| P/E | Price to Earnings |
| PDS | Product Development Services |
| PEG | Price/Earnings to Growth Ratio |
| PF | Provident Fund |
| PV | Present Value |
| RAG | Retrieval-Augmented Generation (AI) |
| RBI | Reserve Bank of India |
| R&D | Research & Development |
| ROA | Return on Assets |
| ROCE | Return on Capital Employed |
| ROE | Return on Equity |
| RPT | Related Party Transaction |
| SaaS | Software as a Service |
| SaMD | Software as a Medical Device |
| SEBI | Securities and Exchange Board of India |
| SOC 2 | System and Organization Controls (Type II) |
| TAM | Total Addressable Market |
| TCV | Total Contract Value |
| TV | Terminal Value (in DCF) |
| US | United States |
| US/EU | United States / European Union |
| WACC | Weighted Average Cost of Capital |
| WC | Working Capital |
| YoY | Year-over-Year |
| ZBB | Zero-Based Budgeting |